Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Active, not recruiting · NCT05887492 · Registry updated 2026-07-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-06 | NCT05887492 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tango Therapeutics, Inc. | 5 |
13 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Florida Cancer Specialists | Sarasota | United States | 47 |
| Henry Ford Health System | Detroit | United States | 147 |
| New York University Langone Health | New York | United States | 18 |
| NEXT Oncology Virginia | Fairfax | United States | 40 |
| NYU Langone Hematology Oncology Associates-Mineola | Mineola | United States | 2 |
| Sarah Cannon Tennessee Oncology | Nashville | United States | 3 |
| SCRI at HealthOne | Denver | United States | 3 |
| START Midwest | Grand Rapids | United States | 79 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| UCLA Hematology/Oncology | Santa Monica | United States | 3 |
| US Oncology Investigational Products Center | Norfolk | United States | 1 |
| US Oncology Investigational Products Center | Dallas | United States | 1 |